RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Grace Therapeutics, Stock

Grace Therapeutics, EBIT 2025

Grace Therapeutics, EBIT

-18.08 M USD

Ticker

GRCE

ISIN

US00439U1043

WKN

A3EP78

In 2025, Grace Therapeutics,'s EBIT was -18.08 M USD, a 59.04% increase from the -11.37 M USD EBIT recorded in the previous year.

The Grace Therapeutics, EBIT history

YEAREBIT (undefined USD)
2030e-
2029e38.89
2028e-0.71
2027e-14.72
2026e-14.48
2025e-18.08
2024-11.37
2023-18.25
2022-15.34
2021-10.72
2020-24.44
2019-33.67
2018-15.35
2017-8.54
2016-7.1
2015-11.01
2014-10.33
2013-6.99
2012-6.57
2011-3.06
2010-1.46
2009-0.71

Grace Therapeutics, Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Grace Therapeutics,, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Grace Therapeutics, from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Grace Therapeutics,’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Grace Therapeutics,. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Grace Therapeutics,’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Grace Therapeutics,’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Grace Therapeutics,’s growth potential.

Grace Therapeutics, Revenue, EBIT and net profit per share

DateGrace Therapeutics, RevenueGrace Therapeutics, EBITGrace Therapeutics, Net Income
2030e122.58 M undefined0 undefined22.34 M undefined
2029e100.86 M undefined38.89 M undefined15.74 M undefined
2028e56.93 M undefined-708,455.5 undefined2.24 M undefined
2027e11.57 M undefined-14.72 M undefined-6.09 M undefined
2026e439,579.2 undefined-14.48 M undefined-16.58 M undefined
2025e0 undefined-18.08 M undefined-18.62 M undefined
20240 undefined-11.37 M undefined-12.85 M undefined
20230 undefined-18.25 M undefined-42.43 M undefined
20220 undefined-15.34 M undefined-9.82 M undefined
2021200,000 undefined-10.72 M undefined-19.68 M undefined
20200 undefined-24.44 M undefined-25.51 M undefined
20190 undefined-33.67 M undefined-39.37 M undefined
20180 undefined-15.35 M undefined-16.76 M undefined
20170 undefined-8.54 M undefined-8.56 M undefined
20160 undefined-7.1 M undefined-4.84 M undefined
20150 undefined-11.01 M undefined-1.47 M undefined
2014480,000 undefined-10.33 M undefined-11.1 M undefined
2013730,000 undefined-6.99 M undefined-6.9 M undefined
2012130,000 undefined-6.57 M undefined-6.56 M undefined
201130,000 undefined-3.06 M undefined-2.95 M undefined
20100 undefined-1.46 M undefined-1.43 M undefined
20090 undefined-710,000 undefined-690,000 undefined

Grace Therapeutics, stock margins

The Grace Therapeutics, margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Grace Therapeutics,. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Grace Therapeutics,.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Grace Therapeutics,'s sales revenue. A higher gross margin percentage indicates that the Grace Therapeutics, retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Grace Therapeutics,'s earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Grace Therapeutics,'s total revenue generated. When comparing the revenue margin year over year, investors can gauge the Grace Therapeutics,'s growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Grace Therapeutics,. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Grace Therapeutics,'s financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Grace Therapeutics, Margin History

Grace Therapeutics, Gross marginGrace Therapeutics, Profit marginGrace Therapeutics, EBIT marginGrace Therapeutics, Profit margin
2030e60 %0 %18.23 %
2029e60 %38.56 %15.6 %
2028e60 %-1.24 %3.93 %
2027e60 %-127.27 %-52.66 %
2026e60 %-3,293.55 %-3,771.22 %
2025e60 %0 %0 %
202460 %0 %0 %
202360 %0 %0 %
202260 %0 %0 %
202160 %-5,360 %-9,840 %
202060 %0 %0 %
201960 %0 %0 %
201860 %0 %0 %
201760 %0 %0 %
201660 %0 %0 %
201560 %0 %0 %
201441.67 %-2,152.08 %-2,312.5 %
201343.84 %-957.53 %-945.21 %
201292.31 %-5,053.85 %-5,046.15 %
2011100 %-10,200 %-9,833.33 %
201060 %0 %0 %
200960 %0 %0 %

Grace Therapeutics, Aktienanalyse

What does Grace Therapeutics, do?

Grace Therapeutics, ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Grace Therapeutics,'s EBIT

Grace Therapeutics,'s Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Grace Therapeutics,'s EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Grace Therapeutics,'s EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Grace Therapeutics,’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Grace Therapeutics, stock

How much did Grace Therapeutics, achieve in EBIT for the current year?

In the current year, Grace Therapeutics, has achieved an EBIT of -18.08 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Grace Therapeutics,.

How has the EBIT of Grace Therapeutics, developed in recent years?

The EBIT of Grace Therapeutics, has increased by 59.044% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Grace Therapeutics,?

The EBIT of Grace Therapeutics, is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Grace Therapeutics, pay?

Over the past 12 months, Grace Therapeutics, paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Grace Therapeutics, is expected to pay a dividend of 0 USD.

What is the dividend yield of Grace Therapeutics,?

The current dividend yield of Grace Therapeutics, is .

When does Grace Therapeutics, pay dividends?

Grace Therapeutics, pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Grace Therapeutics,?

Grace Therapeutics, paid dividends every year for the past 0 years.

What is the dividend of Grace Therapeutics,?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Grace Therapeutics, located?

Grace Therapeutics, is assigned to the 'Health' sector.

Wann musste ich die Aktien von Grace Therapeutics, kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Grace Therapeutics, from 7/1/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/1/2025.

When did Grace Therapeutics, pay the last dividend?

The last dividend was paid out on 7/1/2025.

What was the dividend of Grace Therapeutics, in the year 2024?

In the year 2024, Grace Therapeutics, distributed 0 USD as dividends.

In which currency does Grace Therapeutics, pay out the dividend?

The dividends of Grace Therapeutics, are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Grace Therapeutics,

Our stock analysis for Grace Therapeutics, Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Grace Therapeutics, Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.